Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product areas include orthopedic/joint health, ophthalmic, advanced wound care, post-surgical, aesthetic dermatology, and veterinary products.
Recent Acquisition: On December 30, 2009, Anika acquired 100% of Fidia Advanced Biopolymers S.r.l. ("FAB"), an Italian corporation, for $17.1 million in cash and approximately 1.98 million shares of Anika common stock. This acquisition expanded Anika's portfolio into advanced wound care and additional orthopedic regenerative medicine products.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenue | $12,466,087 | $9,200,324 |
| Product Revenue | $11,642,050 | $8,519,073 |
| Net Income | $714,280 | $522,720 |
| Diluted EPS | $0.05 | $0.05 |
| Operating Cash Flow | $19,485 | ($1,098,366) |
| Cash and Equivalents (End of Period) | $23,167,641 | $40,426,703 |
| Total Debt Outstanding | $14,000,000 | $14,400,000 (Est. based on payments) |
| Product Gross Margin | 56% | 62% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35.5% year-over-year, driven primarily by a 36.7% increase in product revenue.
- Orthopedic/Joint Health: Increased 34.4% to $6.92 million, fueled by domestic ORTHOVISC sales and international MONOVISC sales.
- New Segments: Advanced Wound Care ($688,694) and Post Surgical ($578,547) revenues are new contributions from the FAB acquisition.
- Ophthalmic: Decreased 2.3% to $2.58 million due to order timing and inventory management by partners.
- Profitability: Net income increased 36.6% to $714,280. However, product gross margin declined from 62% to 56%, attributed to the lower volume and outsourced manufacturing costs of the newly acquired FAB subsidiary.
- Operating Expenses:
- R&D: Decreased 15% to $1.88 million, largely due to the completion of the MONOVISC clinical trial in 2009.
- SG&A: Increased 41% to $4.29 million, primarily due to the inclusion of FAB operations and costs related to MONOVISC marketing preparation.
- Cash Flow: Operating cash flow turned positive ($19,485) compared to a negative $1.1 million in the prior year, despite a decrease in cash balances due to investing and financing activities.
- Debt: The company made a $400,000 principal payment on its long-term debt. The interest rate on the credit facility was adjusted upward following the FAB acquisition.
Guidance, Outlook, and Risks
- Outlook: Management expects joint health product sales to increase in 2010. They anticipate a modest increase in general and administrative expenses but a significant increase in selling expenses as they prepare for the direct commercialization of MONOVISC in the U.S.
- Facility Transition: The company is transitioning manufacturing from Woburn, MA to a new Bedford, MA facility. This transition is expected to cause a small decline in U.S. gross margins in 2010 and will add over $2.2 million to annual depreciation once fully operational.
- Regulatory: The FDA PMA filing for MONOVISC is under review. The company has resolved a previous FDA Warning Letter regarding its Woburn facility but continues to undergo inspections.
- Risks:
- Customer Concentration: Two customers (DePuy Mitek and Bausch & Lomb) accounted for 66.8% of product revenue in Q1 2010.
- Integration: Risks associated with integrating FAB's operations and R&D pipeline.
- Financing: Future funding requirements may necessitate additional equity or debt financing if operations expand faster than cash generation.
- Currency: Unfavorable exchange rate fluctuations impacted the goodwill balance by $2.06 million due to the consolidation of the Italian subsidiary.
Investor Verification Checklist
- MONOVISC Approval Status: Verify the timeline for FDA approval of MONOVISC, a key growth driver for the U.S. market.
- Gross Margin Recovery: Monitor the transition of FAB manufacturing to the Bedford facility to assess if gross margins can recover from the current 56% level.
- Customer Concentration: Review the stability of relationships with DePuy Mitek (45.5% of product revenue) and Bausch & Lomb (21.3% of product revenue).
- Debt Covenants: Confirm compliance with the amended credit agreement terms, including the increased interest rate and the pledge of 65% of FAB stock.
- Facility Validation: Track the completion of the Bedford, MA facility validation, expected in late 2010, to ensure no delays in production capacity.